Community-associated methicillin-resistant Staphylococcus aureus infections in a pediatric intensive care unit

Abstract

Introduction: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection is an increasing problem worldwide. In developing countries, there is little data on CA-MRSA infection in children. This study reviewed the clinical features and outcomes of children admitted in a Tunisian pediatric intensive care unit with severe CA-MRSA infections. Methodology: Retrospective chart review of patients coded for CA-MRSA over 10 years. Results: There were 14 (0.32% of all admissions) patients identified with severe CA-MRSA infections. The median age was three months (range, 0.5-156 months). All patients had pulmonary involvement. Six children (42.8%) developed septic shock. Two (14.3%) patients had multifocal infection with deep venous thrombosis. Two (14.3%) patients died. Conclusions: Severe CA-MRSA pneumonia dominated presentation. The mortality of CA-MRSA infection in our series is lower than that previously reported.

Community-associated methicillin-resistant Staphylococcus aureus in children treated in Uruguay

“…Regarding the outcome of children with CA-MRSA invasive diseases, we observed a rate of admissions to ICU (35.4%) and a mortality figure (34.7%) similar to that previously reported in the USA [21] but higher than that found in children from Tunisia [34]. However, these CA-MRSA isolates displayed microbiological characteristics similar to those recovered from children with invasive infections and better clinical outcome (Table 3).…”

Community-Associated Methicillin-Resistant Staphylococcus aureus Case Studies

“…Despite the relatively low overall MRSA frequency, severe cases of invasive CA-MRSA requiring admission to the pediatric ICU have been documented over a 10 year period in Tunisia with an increase in incidence over the last year of the study [95]. Despite these relatively low numbers, major international lineages have been reported from the region, such as the predominant European CA-MRSA lineage ST80 in Algeria, Egypt, and Tunisia [96, 97] (Table 1).…”

Inhibiting PSMα-induced neutrophil necroptosis protects mice with MRSA pneumonia by blocking the agr system

“…Linezolid and vancomycin are the most reliable therapeutic agents against MRSA pneumonia 2 , 3 ; however, vancomycin-resistant S. aureus (VRSA) and linezolid-resistant S. aureus (LRSA) have alarmingly emerged in severe MRSA pneumonia cases 4 , 5 . Moreover, the development of antibiotic resistance is associated with high morbidity and mortality risk, particularly in the intensive care unit 6 . Therefore, novel strategies are urgently needed for treating and preventing invasive MRSA infections.…”